Orlistat Abolishes Postprandial Lipid Peaking

Z Abejuela; A Macaballug; J Sumpio; M Zacarias; L Mercado

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Orlistat Abolishes Postprandial Lipid Peaking

Author(s):

Z R Abejuela^1,*,

A G Macaballug²,

J P Sumpio³,

M B Zacarias³,

L B Mercado⁴

1Sections of Endocrinology and Metabolism University Of Santo Tomas Hospital, zabejuela@yahoo.com, Philippines

2Sections of Endocrinology and Metabolism University Of Santo Tomas Hospital, Philippines

3Dietary Services, University Of Santo Tomas Hospital, Manila, Philippines

4Cardiology,University Of Santo Tomas Hospital, Manila, *, Philippines

International Journal of Endocrinology and Metabolism:Vol. 7, issue 3; 179-186

Article type:Research Article

Received:Nov 15, 2008

Accepted:Aug 01, 2009

How to Cite:Z R AbejuelaA G MacaballugJ P SumpioM B ZacariasL B MercadoOrlistat Abolishes Postprandial Lipid Peaking.Int J Endocrinol Metab.7(3):179-186.

Abstract

Postprandial hyperlipemia is associated with the development of cardiovascular disease. Orlistat is a pancreatic lipase inhibitor that reduces fat absorption from the diet by inhibition of hy-drolysis of triglycerides. Since the effect of orlis-tat on postprandial lipemia has not been fully elucidated, we studied the effect of orlistat on postprandial lipemia after a 50% oral fat chal-lenge test (OFCT). Materials and Methods: Twenty-seven healthy volunteers, aged 18-45 years old, with normal body mass index (BMI) and normal fasting lipid levels, were studied. The control group (n=15) was given the 50% OFCT while the study/orlistat group (n=12), was given 120 mg orlistat followed by intake of the 50% OFCT. Total cholesterol (TC), triglycerides (TG), high density lipoprotein (HDL) and low density lipoprotein (LDL) were determined at baseline and serially over a 6-hour period. Re-sults: In the control group, TC, TG and HDL peaked in the 4th hour. This lipid peaking was not observed in the orlistat group. Percentage change between baseline to the 4th hour values in the control vs. the study group were, respec-tively, as follows: TC = 65.80% vs. -1.60%; TG = 262.64% vs. 24.74%; and HDL = 205.26% vs. -1.43%. The mean postprandial levels for TC, TG and LDL were well within the normal fasting cut-offs of <6.20 mmol/L, <2.26 mmol/L, and < 4.14 mmol/L respectively throughout the entire 6-hour study period. Conclusion: Orlistat ab-olished the peaking of TC, TG, and HDL after a 50% OFCT. Nonetheless, lipid values were main-tained within normal fasting levels in the orlistat group.

Keywords

Cardiovascular disease

Full Text

Full text is available in PDF

comments